Feature | June 12, 2015

Follow-up PET/CT Altering Patient Management for Non-Hodgkin Lymphoma

Molecular imaging found to be 95 percent sensitive in catching early recurrence

non-Hodgkins lymphoma, PET/CT, recurrence, SNMMI 2015

June 12, 2015 - Post-treatment surveillance with molecular imaging could mean the early start of a new, life-saving treatment for non-Hodgkin lymphoma (NHL), said researchers at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

NHL - a potentially devastating cancer of the blood and immune system - is the fifth most prevalent cancer in America, according to lead author Mehdi Taghipour, M.D., a research fellow from the department of radiology at the Johns Hopkins Medical Institutions in Baltimore, Maryland. A majority of NHL patients are treated successfully with frontline chemotherapy, but about 20-50 percent of patients with aggressive lymphoma are expected to relapse within three years. Functional and structural imaging with a combination of positron emission tomography and computed tomography (PET/CT) has the potential to catch a relapse in its earliest stages.

"A permanent cure may still be achieved using salvage chemotherapy, but early diagnosis of a relapse is essential," said Taghipour. "PET/CT imaging is superior to conventional imaging for NHL, but the role of post-treatment PET/CT has been controversial. Our study proves that 39 percent of follow-up PET/CT scans added clinical value, which represents a significant improvement in NHL patient care."

The study included a collective 560 PET/CT scans from 204 patients. Imaging was performed six months or more after completion of primary therapy. Researchers assessed the value of follow-up PET/CT by conducting statistical analysis to determine changes in patient management and evaluated the accuracy of these scans comparing to either histopathology or additional six-month follow-up.

Results of the study showed that the sensitivity of PET/CT for detecting relapsed NHL was 95.1 percent. Specificity, or the ability to rule out NHL, was gauged at 90.5 percent. Positive and negative predictive values, which provide insight into the ability of the scan to accurately determine the presence or absence of a disease, were 84.5 percent and 97.1 percent, respectively. Lastly, overall accuracy of follow-up PET/CT with the common imaging agent fluorodeoxyglucose (FDG), which provides a map of cellular metabolic activity, was 92.1 percent.

Follow-up PET/CT led to changes in patient management in 17 percent of scan times, and new treatments were initiated after 15.7 percent of scan times. More than 69 percent of scans were performed without prior clinical suspicion of recurrence, and 30.7 percent of scans were ordered because of suspected disease, More than 22 percent of follow-up scans showed suspected disease when there was no clinical suspicion for disease recurrence, and presence of disease was ruled out in 17.4 percent of scans while the treating physician suspected recurrence prior to the scan.

An estimated 71,850 people will be diagnosed with NHL and 19,790 people will die of the disease this year, according to 2015 statistics from the American Cancer Society.

For more information: www.snmmi.org

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
German Team Optimizing Therapy Planning for Cancers of the Liver
News | Interventional Radiology | August 29, 2017
Radioembolization is a therapy method used for liver tumors that are uncurable with surgery or chemotherapy. Thorough...
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init